Live from the NIH registry
Studies recruiting near Fort Worth right now
Top 25 of 606 recruiting studies, sorted by proximity — each links to its official registry page
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Heart Failure
Phase 3
Interventional 1,500 participants sought
CON-10301, Fort Worth, TX — Fort Worth, Texas (4.2 mi)
· Sponsor: Colorado Prevention Center
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Cook Children's Medical Center — Fort Worth, Texas (4.2 mi)
· Sponsor: National Cancer Institute (NCI)
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Solid Tumors
Phase 2
Interventional 170 participants sought
Texas Oncology-Bedford — Bedford, Texas (12.6 mi)
· Sponsor: Mirati Therapeutics Inc.
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas (4.2 mi)
· Sponsor: SWOG Cancer Research Network
PAS-004 in Patients With Advanced Solid Tumors
RAS Mutation, NF1 Mutation
Phase 1
Interventional 48 participants sought
NEXT Oncology — Irving, Texas (23.3 mi)
· Sponsor: Pasithea Therapeutics Corp.
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Colitis Ulcerative
Phase 2
Interventional 204 participants sought
Texas Digestive Disease Consultants - Southlake- Site Number : 8400015 — Southlake, Texas (16.6 mi)
· Sponsor: Sanofi
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Solid Tumor, Non-Small-Cell Lung Cancer
Phase 1
Interventional 364 participants sought
NEXT Oncology Dallas — Irving, Texas (23.3 mi)
· Sponsor: Astellas Pharma Inc
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Locally Advanced Cervical Cancer
Phase 3
Interventional 800 participants sought
Research Site — Fort Worth, Texas (4.2 mi)
· Sponsor: AstraZeneca
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Ovarian Cancer Recurrent
Phase 1, Phase 2
Interventional 460 participants sought
Texas Oncology - DFW ( Site 8000) — Fort Worth, Texas (4.2 mi)
· Sponsor: Merck Sharp & Dohme LLC
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Fort Worth, Texas (4.2 mi)
· Sponsor: AstraZeneca
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer
Phase 3
Interventional 1,000 participants sought
University of Texas Southwestern Simmons Cancer Center - Fort Worth — Fort Worth, Texas (4.2 mi)
· Sponsor: Pfizer
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3
Interventional 1,200 participants sought
The Center for Cancer and Blood Disorders ( Site 0032) — Fort Worth, Texas (4.2 mi)
· Sponsor: Merck Sharp & Dohme LLC
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
MTAP-deleted Solid Tumors
Phase 1, Phase 2
Interventional 450 participants sought
NEXT Dallas - Oncology Department — Irving, Texas (23.3 mi)
· Sponsor: Bayer
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Ulcerative Colitis
Phase 4
Interventional 65 participants sought
Texas Digestive Disease Consultants (TDDC), Southlake — Southlake, Texas (16.6 mi)
· Sponsor: Takeda
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Cystic Fibrosis
N/A
Observational 400 participants sought
Cook Children's Medical Center — Fort Worth, Texas (4.2 mi)
· Sponsor: Nicole Hamblett
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Gout
Phase 3
Interventional 500 participants sought
Alliance Clinical Lewisville (Epic Clinical Research) — Lewisville, Texas (27.5 mi)
· Sponsor: Crystalys Therapeutics
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma
Phase 1
Interventional 174 participants sought
NEXT Oncology — Irving, Texas (23.3 mi)
· Sponsor: Avacta Life Sciences Ltd
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Cancer, Tumor, Solid
Phase 1, Phase 2
Interventional 168 participants sought
NEXT Dallas — Irving, Texas (23.3 mi)
· Sponsor: OncoResponse, Inc.
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Phase 3
Interventional 1,530 participants sought
John Peter Smith Hospital ( Site 0106) — Fort Worth, Texas (4.2 mi)
· Sponsor: Merck Sharp & Dohme LLC
Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis
Rheumatoid Arthritis
N/A
Interventional 40 participants sought
Precision Comprehensive Clinical Research Solutions — Colleyville, Texas (13.1 mi)
· Sponsor: Surf Therapeutics
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
Phase 1
Interventional 1,006 participants sought
US Oncology Investigational Product Center (IPC) — Irving, Texas (23.3 mi)
· Sponsor: Seagen, a wholly owned subsidiary of Pfizer
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Malignant Glioma
Phase 1, Phase 2
Interventional 132 participants sought
Cook Children's Medical Center — Fort Worth, Texas (4.2 mi)
· Sponsor: National Cancer Institute (NCI)
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
Acute Respiratory Distress Syndrome (ARDS), ARDS
Phase 2
Interventional 200 participants sought
Baylor All Saints Medical Center — Fort Worth, Texas (4.2 mi)
· Sponsor: PPD Development, LP
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System
Atrial Fibrillation
N/A
Interventional 276 participants sought
Baylor Scott and White Research Institute — Fort Worth, Texas (4.2 mi)
· Sponsor: Biosense Webster, Inc.
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
Irritability Associated With Autism Spectrum Disorder
Phase 3
Interventional 160 participants sought
North Pointe Psychiatry — Flower Mound, Texas (21.7 mi)
· Sponsor: Intra-Cellular Therapies, Inc.